# Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

> **NCT07706933** · NA · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 456 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Abemaciclib/Ribociclib

## Key facts

- **NCT ID:** NCT07706933
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2033-06-30
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706933, "Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07706933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*